

COVAX

CEPI



unicef



COVAX Manufacturing Taskforce: Achievements and Challenges Ahead

Melanie Saville

CEPI, Director of Vaccine Research and Development

COVAX Supply chain & Manufacturing Taskforce vision and objectives

Strengthen vaccine manufacturing to secure more doses



Support COVAX mission to end acute phase of the pandemic by end 2021



Optimise the number of vaccine doses manufactured in the short term



Prioritise doses for COVAX with a special emphasis on AMC92 to ensure greater equity



Mitigate unintended impact on other vaccines and health products



Initiate regional health security through establishment of sustainable regional long-term manufacturing of vaccines

Manufacturing Taskforce Accomplishments

Workstream 1 – Immediate COVAX Response

Activity	Accomplishments
Supply Chain Efficiency	<ul style="list-style-type: none">✓ Launched COVAX Marketplace July 2021✓ Onboarded 17 partner suppliers and manufacturers✓ Completed two matches resulting in ~78M vaccine doses✓ Engaged with 30 additional partners
Free Flow of Goods	<ul style="list-style-type: none">✓ Support of WTO engagements (e.g., Ministerial Conference, trade investment discussions, etc.)✓ Raised awareness of supplies and criticality of access

Workstream 2 – Mid-Term COVAX Response

Activity	Accomplishments
Fill & Finish Matchmaking	<ul style="list-style-type: none">✓ Completed analysis of single dose vs. multidose vials and impact to vaccine availability and supply✓ Transitioned upgrade of F&F match-making to within the COVAX Marketplace
Workforce Development	<ul style="list-style-type: none">✓ Completed analysis of workforce development needs via interviews with industry associations, vaccine manufacturers and training org; identified longer-term need and transitioned to Workstream 3✓ Travel restrictions and priority immunization of critical workforce resolved as vaccines more available worldwide

Workstream 3 – Long-Term Sustainable Manufacturing

Activity	Accomplishments
South Africa mRNA Hub	<ul style="list-style-type: none">✓ Letter of Intent signed to established Hub signed 30 July✓ Successfully held field trip to South Africa 6-9 September – milestones and baseline budgets established✓ Conducted funders' meeting 22 September


Manufacturing Taskforce WS3

WS3 ambition is to improve long-term LMIC health security via two key objectives and enablers




Objective 1

Expand capabilities of existing manufacturers in LMICs



Objective 2







Establish sustainable capacity in regions with no significant capacity



Enablers

Identify & implement innovations and develop normative frameworks

Workstream 3 – Sustainable Manufacturing: Near-Term Priorities

	Priority
 1/ Tech Innovation, Selection & IP	<ul style="list-style-type: none"> • Select early-stage tech donors to develop local Covid mRNA vaccine • Issue call for expression of interest to receive training at the Hub
 2/ Product dev., Manufacturing & Plants	<ul style="list-style-type: none"> • Assess product development needs for SA hub
 3/ Regulatory & Clinical Dev.	<ul style="list-style-type: none"> • Support clinical development for mRNA techs
 4/ Business Model & Financing	<ul style="list-style-type: none"> • Finalize demand / offer mapping to assess need for additional capacity
 5/ Funding & Governance	<ul style="list-style-type: none"> • Follow up on conversations with potential funders
 6/ Workforce development	<ul style="list-style-type: none"> • Identify potential trainers & initiate training • Issue a call for expression of interest to host workforce training hub

Working Groups